|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM072321652 |
003 |
DE-627 |
005 |
20231222013951.0 |
007 |
tu |
008 |
231222s1981 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0241.xml
|
035 |
|
|
|a (DE-627)NLM072321652
|
035 |
|
|
|a (NLM)7255509
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Hartmann, A
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Effect of pentoxifylline on regional cerebral blood flow in patients with cerebrovascular disease
|
264 |
|
1 |
|c 1981
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 25.09.1981
|
500 |
|
|
|a Date Revised 21.11.2013
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a A previous study showed that regional cerebral blood flow, measured following intra-arterial injection of 133Xenon, increased by at least 15% in one-third of all areas investigated in 25 patients with different types of dementia after a 2-weeks' period of intravenous treatment with 600 mg pentoxifylline per day. In the present studies, 10 patients were treated orally with 400 mg pentoxifylline 3-times daily for 4 weeks and 10 untreated patients served as controls. Regional cerebral blood flow was measured over both hemispheres using a new non-invasive technique by inhalation of 133Xenon gas. Bihemispheric cerebral blood flow increased by 15.9% in the pentoxifylline group and by 1.7% in the controls. Hypoemic areas, in particular, showed a distinctly higher increase (+20.1%) in blood flow after pentoxifylline compared to controls (+0.7%), and these hypoemic areas were apparently more influenced than hyperemic or normoemic regions. These findings were confirmed by a second controlled series. These data suggest an improvement of cerebral blood flow by pentoxifylline in a certain number of brain tissue areas if the drug is given over periods of at least 2 weeks in patients with cerebrovascular disease and other types of dementia
|
650 |
|
4 |
|a Clinical Trial
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Randomized Controlled Trial
|
650 |
|
7 |
|a Theobromine
|2 NLM
|
650 |
|
7 |
|a OBD445WZ5P
|2 NLM
|
650 |
|
7 |
|a Pentoxifylline
|2 NLM
|
650 |
|
7 |
|a SD6QCT3TSU
|2 NLM
|
773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 2(1981), 8 vom: 16., Seite 528-31
|w (DE-627)NLM023961570
|
773 |
1 |
8 |
|g volume:2
|g year:1981
|g number:8
|g day:16
|g pages:528-31
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_120
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 2
|j 1981
|e 8
|b 16
|h 528-31
|